Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.
Skye Bioscience, Inc. reports clinical-stage biotechnology developments focused on metabolic health disorders, obesity and overweight. The company's lead program, nimacimab, is a peripherally restricted monoclonal antibody inhibitor of the CB1 receptor being evaluated in the CBeyond Phase 2a program, including monotherapy and combination work with GLP-1 or other incretin-based therapies.
Recurring updates cover clinical data from CBeyond, higher-dose safety and pharmacokinetic work, regulatory feedback on follow-on trial design, manufacturing and formulation activities, scientific conference presentations, financial results and corporate outlooks. Skye also discusses its broader strategy of developing molecules that modulate G-protein-coupled receptors.
Skye Bioscience, a clinical-stage biopharmaceutical company specializing in endocannabinoid system therapies, will participate in Piper Sandler's Virtual Obesity Day on June 26, 2024. This event, linked to the ADA 2024 Conference, features presentations by key opinion leaders and discussions with companies developing obesity treatments. Skye Bioscience's CEO Punit Dhillon, Chief Development Officer Tu Diep, and Chief Scientific Officer Chris Twitty will be part of a fireside chat from 11:30-11:55 a.m. ET. Piper Sandler clients can register through their representatives.
Skye Bioscience (Nasdaq: SKYE) announced the discontinuation of its SBI-100 Ophthalmic Emulsion (OE) program after it failed to meet the primary endpoint in a Phase 2a trial for glaucoma and ocular hypertension. The study, involving 56 patients, found no statistically significant improvement in intraocular pressure compared to placebo. Consequently, Skye will terminate all R&D related to SBI-100 OE and divert resources to its metabolic program. The company plans to initiate a Phase 2 obesity trial for its CB1 inhibitor, Nimacimab, in Q3 2024 and expects its cash runway to extend into 2027.
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech firm, will present at the Jefferies Global Healthcare Conference in NYC from June 5-6, 2024. CEO and Chair Punit Dhillon will outline the company's progress in obesity and glaucoma treatments on June 5 at 5:00 p.m. ET. A webcast of the presentation will be available.
Skye Bioscience presented new data at the ARVO 2024 Annual Meeting showcasing a novel library of synthetic cannabinoids for ocular diseases. The study focused on dry eye disease and chronic ocular pain, identifying three potential therapeutic candidates with innovative mechanisms of action. Skye aims to develop drugs modulating the endocannabinoid system to treat diverse ocular pathologies.
Skye Bioscience, Inc. (Nasdaq: SKYE) will present two posters at the ARVO 2024 Annual Meeting focusing on their Phase 1 study of a novel ocular drug and the development of synthetic endocannabinoid agonists. The event will take place in Seattle, Washington from May 5-9, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.